Laura Vidal

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Timothy A. Yap, Laura Vidal, Jan Adam et al. · Journal of Clinical Oncology · 2010 · 342 citations · Full text

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Jean‐Sébastien Frenel, J.W. Kim, Nanda Aryal et al. · Annals of Oncology · 2022 · 140 citations

Post-hoc Analyses, Medicine, Subsequent Chemotherapy +8

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Michael Friedländer, Val Gebski, Emma Gibbs et al. · The Lancet Oncology · 2018 · 135 citations · Full text

Olaparib Maintenance, Health-related Quality, Medicine +9

Enhanced <i>In vitro</i> and <i>In vivo</i> Cytotoxicity of Combined Reovirus and Radiotherapy

Katie Twigger, Laura Vidal, Christine L. White et al. · Clinical Cancer Research · 2008 · 103 citations

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

L. Rhoda Molife, Peter C.C. Fong, Luisa Paccagnella et al. · British Journal of Cancer · 2010 · 85 citations · Full text